Severely heated therapeutic factor VIII concentrate of high specific activity.
A new method for the manufacture of a heated factor VIII concentrate of high specific activity (2-6 IU factor VIII:C/mg protein) has been developed. Addition of heparin to cryoprecipitate extract at acid pH precipitated fibrinogen and fibronectin. Factor VIII was then recovered from the supernatant by precipitation with glycine and sodium chloride. After re-solution and desalting on Sephadex G-25, the concentrate was sterile-filtered and lyophilised. The dried product was stable to heating in the final container at 80 degrees C for 72 h. Data from 25 consecutive batches of concentrate prepared from 1,200-1,500 kg plasma pools are presented. The mean final yield of heated product was 190 IU factor VIII:C/kg plasma. The concentrate has been found to be safe and effective in clinical use.
Winkelman
L
L
Plasma Fractionation Laboratory, Churchill Hospital, Oxford, UK.
Owen
N E
NE
Evans
D R
DR
Evans
H
H
Haddon
M E
ME
Smith
J K
JK
Prince
P J
PJ
Williams
J D
JD
Lane
R S
RS
D011232:Chemical Precipitation; D004355:Drug Stability; D005169:Factor VIII / Q000008:administration & dosage / Q000009:adverse effects / Q000302:isolation & purification*; D005615:Freezing; D005998:Glycine; D006493:Heparin; D006358:Hot Temperature; D006801:Humans; D012492:Salts / Q000302:isolation & purification; D012965:Sodium Chloride
D012492:Salts; D012965:Sodium Chloride; D005169:Factor VIII; D006493:Heparin; D005998:Glycine